atrial fibrillation - prevention - patient with history of atrial fibrillation clinical trials results meta-analysis

<h1> <a href="TM10-120-prevention-atrial fibrillation" > <strong>atrial fibrillation</strong> - prevention </a> - patient with history of atrial fibrillation trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t9355.htm"> GISSI-AF (Disertori), 2009 </a> <br> NCT00376272 </td> <td> valsartan<br>  <i>versus</i> <br> placebo </td> <td> patients in sinus rhythm but with either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks and with underlying cardiovascular disease, diabetes, or left atrial enlargement </td> <td> follow-up 1 year<br> n=722/720<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9531.htm"> CAPRAF (Tveit), 2007 </a> <br> NCT00130975 </td> <td> candesartan 8 mg once daily for 3-6 weeks before and candesartan 16 mg once daily for 6 months after electrical cardioversion<br>  <i>versus</i> <br> placebo </td> <td> patients undergoing electrical cardioversion for persistent AF </td> <td> follow-up 6 months<br> n=86/85<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9688.htm"> ACTIVE I, 2009 </a> <br> NCT00249795 </td> <td> irbesartan 300mg once daily<br>  <i>versus</i> <br> placebo </td> <td> patients with atrial fibrillation and with a systolic blood pressure of at least 110 mmHg associated with at least one major risk of vascular events </td> <td> follow-up 4.1 years<br> n=4518/4498<br> Factorial plan<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9752.htm"> Almroth, 2009 </a> <br> </td> <td> atorvastatin 80 mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients with persistent atrial fibrillation undergoing electrical cardioversion </td> <td> follow-up <br> n=118/116<br> Parallel groups<br> double blind <br> Sweden </td> </tr> <tr> <td> <a href="../TRC_t9773.htm"> Tveit, 2004 </a> <br> </td> <td> pravastatin 40 mg<br>  <i>versus</i> <br> standard therapy </td> <td> AF >48 h and scheduled EC </td> <td> follow-up 6 weeks<br> n=51/51<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9774.htm"> MIRACL (sub-group) (Schwartz), 2004 </a> <br> </td> <td> atorvastatin 80 mg<br>  <i>versus</i> <br> placebo </td> <td> Acute coronary syndrome </td> <td> follow-up 16 weeks<br> n=118/108<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9776.htm"> Ozaydin, 2006 </a> <br> </td> <td> atorvastatin 10 mg<br>  <i>versus</i> <br> standard therapy </td> <td> Persistent AF and scheduled EC </td> <td> follow-up 3 months<br> n=24/24<br> <br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t9778.htm"> Dernellis, 2006 </a> <br> </td> <td> atorvastatin 20–40 mg<br>  <i>versus</i> <br> placebo </td> <td> Paroxysmal AF with CRP between 0.8 and 13 mg/L </td> <td> follow-up 4–6 months<br> n=40/40<br> <br> NA <br> </td> </tr> <tr> <td> <a href="../TRC_t9800.htm"> Van den Burg, 1995 </a> <br> </td> <td> lisinopril<br>  <i>versus</i> <br> placebo </td> <td> atrial fibrillation, congestive heart failure </td> <td> follow-up 84 days<br> n=7/11<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9801.htm"> Ueng, 2003 </a> <br> </td> <td> enalapril<br>  <i>versus</i> <br> control </td> <td> atrial fibrillation </td> <td> follow-up 270 days (range 61-575d)<br> n=70/75<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t9802.htm"> Madrid, 2002 </a> <br> </td> <td> irbesartan<br>  <i>versus</i> <br> control </td> <td> atrial fibrillation </td> <td> follow-up 254 d (range 60-710)<br> n=79/75<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t9482.htm"> ANTIPAF, </a> <br> NCT00098137 </td> <td> olmesartan 40mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients with paroxysmal atrial fibrillation </td> <td> follow-up 12 months<br> n=-9/-9<br> Parallel groups<br> double blind <br> germany </td> </tr> <tr> <td> <a href="../TRC_t9540.htm"> Brown, </a> <br> NCT00141778 </td> <td> ramipril or spironolactone<br>  <i>versus</i> <br> placebo </td> <td> AF following CPB surgery </td> <td> follow-up <br> n=777/0<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9690.htm"> STOP-AF, </a> <br> NCT00252967 </td> <td> atorvastatin 80mg daily<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>GISSI-AF (Disertori), 2009 : </b> Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni GValsartan for prevention of recurrent atrial fibrillation. <i>N Engl J Med 2009 Apr 16;360:1606-17</i> [PMID 19369667] </p> <p> <b>CAPRAF (Tveit), 2007 : </b> Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith PCandesartan in the prevention of relapsing atrial fibrillation. <i>Int J Cardiol 2007;120:85-91</i> [PMID 17113170] </p> <p> <b>Almroth, 2009 : </b> Almroth H, Höglund N, Boman K, Englund A, Jensen S, Kjellman B, Tornvall P, Rosenqvist MAtorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. <i>Eur Heart J 2009;30:827-33</i> [PMID 19202157] </p> <p> <b>Tveit, 2004 : </b> Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad LAnalysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. <i>Am J Cardiol 2004;93:780-2</i> [PMID 15019894] 10.1016/j.amjcard.2003.12.009 </p> <p> <b>MIRACL (sub-group) (Schwartz), 2004 : </b> Schwartz GG, Olsson AG, Chaitman B, Goldberger J, Szarek M <i>Circulation 2004;110 Suppl:S740</i> [PMID ] </p> <p> <b>Ozaydin, 2006 : </b> Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas AEffect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. <i>Am J Cardiol 2006;97:1490-3</i> [PMID 16679090] 10.1016/j.amjcard.2005.11.082 </p> <p> <b>Dernellis, 2006 : </b> Dernellis J, Panaretou MEffect of C-reactive protein reduction on paroxysmal atrial fibrillation. <i>Am Heart J 2005;150:1064</i> [PMID 16290998] 10.1016/j.ahj.2005.06.032 </p> <p> <b>Van den Burg, 1995 : </b> Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KIEffects of lisinopril in patients with heart failure and chronic atrial fibrillation. <i>J Card Fail 1995;1:355-63</i> [PMID 12836710] </p> <p> <b>Ueng, 2003 : </b> Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SAUse of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. <i>Eur Heart J 2003;24:2090-8</i> [PMID 14643269] </p> <p> <b>Madrid, 2002 : </b> Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro CUse of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. <i>Circulation 2002;106:331-6</i> [PMID 12119249] </p> <p> <b>Adabag, : </b> Adabag AS, Mithani S, Al Aloul B, Collins D, Bertog S, Bloomfield HEEfficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. <i>Am Heart J 2009 May;157:913-8</i> [PMID 19376321] 10.1016/j.ahj.2009.02.015 </p>